Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Details
Serval ID
serval:BIB_7C80EE8E129C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Journal
European journal of surgical oncology
ISSN
1532-2157 (Electronic)
ISSN-L
0748-7983
Publication state
Published
Issued date
02/2022
Peer-reviewed
Oui
Volume
48
Number
2
Pages
383-390
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
The effects of cytotoxic chemotherapy on the expression of programmed cell death 1 (PD-1) and its ligand (PD-L1) in cancer cells and peritumoral cells are unclear. The aim of this study was to investigate the impact of neoadjuvant chemotherapy on PD-1 and PD-L1 expression in adenocarcinomas of the gastroesophageal junction.
PD-1 and PD-L1 expression in cancer cells and tumor-infiltrating lymphocytes in paired diagnostic biopsies and surgical specimens from patients with pretreated and curatively resected adenocarcinomas of the gastroesophageal junction were evaluated by immunohistochemistry.
Paired tumor samples were available from 40 patients. PD-1 expression in cancer cells (p < 0.001; Exact Symmetry Test) and tumor-infiltrating lymphocytes (p < 0.001; Exact Symmetry Test) increased significantly after neoadjuvant therapy. Furthermore, we observed a significant decrease in PD-L1 expression in cancer cells (p = 0.003) after neoadjuvant therapy was observed.
In this study we could show that tumor-cell expression of PD-1 and PD-L1 was significantly altered in patients with adenocarcinomas of the gastroesophageal junction after receiving neoadjuvant chemotherapy. Based on these observations, patients might profit from the combined use of cytotoxic chemotherapy and the blockade of the PD-1 axis.
PD-1 and PD-L1 expression in cancer cells and tumor-infiltrating lymphocytes in paired diagnostic biopsies and surgical specimens from patients with pretreated and curatively resected adenocarcinomas of the gastroesophageal junction were evaluated by immunohistochemistry.
Paired tumor samples were available from 40 patients. PD-1 expression in cancer cells (p < 0.001; Exact Symmetry Test) and tumor-infiltrating lymphocytes (p < 0.001; Exact Symmetry Test) increased significantly after neoadjuvant therapy. Furthermore, we observed a significant decrease in PD-L1 expression in cancer cells (p = 0.003) after neoadjuvant therapy was observed.
In this study we could show that tumor-cell expression of PD-1 and PD-L1 was significantly altered in patients with adenocarcinomas of the gastroesophageal junction after receiving neoadjuvant chemotherapy. Based on these observations, patients might profit from the combined use of cytotoxic chemotherapy and the blockade of the PD-1 axis.
Keywords
Adenocarcinoma/drug therapy, Adenocarcinoma/metabolism, Adenocarcinoma/pathology, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, B7-H1 Antigen/metabolism, Esophageal Neoplasms/drug therapy, Esophageal Neoplasms/metabolism, Esophageal Neoplasms/pathology, Esophagogastric Junction, Female, Humans, Immunohistochemistry, Lymphocytes, Tumor-Infiltrating/metabolism, Male, Middle Aged, Neoadjuvant Therapy, Programmed Cell Death 1 Receptor/metabolism, Treatment Outcome, Adenocarcinoma of the gastroesophageal junction, Immunotherapy, Neoadjuvant chemotherapy, Programmed cell death (PD-1), Programmed cell death ligand (PD-L1)
Pubmed
Web of science
Create date
15/03/2022 13:08
Last modification date
17/05/2022 6:36
Usage data
